FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Library",
  "id": "179632",
  "meta": {
    "versionId": "4",
    "lastUpdated": "2023-12-15T13:02:51.862Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Library/179632",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "179632",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113883.4.642.40.44.28.2"
    }
  ],
  "version": "1.0.0-ballot3",
  "title": "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
  "status": "active",
  "experimental": false,
  "type": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/library-type",
        "code": "asset-collection",
        "display": "Asset Collection"
      }
    ]
  },
  "subjectReference": {
    "reference": "Group/179619",
    "type": "Group",
    "display": "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"
  },
  "date": "2023-11-26T18:15:27.442Z",
  "publisher": "HL7 International / Clinical Decision Support",
  "contact": [
    {
      "name": "HL7 International / Clinical Decision Support",
      "telecom": [
        {
          "system": "url",
          "value": "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "description": "11 excluded studies",
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "SystematicReviewExcludedStudies",
            "display": "SystematicReviewExcludedStudies"
          }
        ]
      }
    }
  ],
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code": "001",
          "display": "World"
        }
      ]
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "author": [
    {
      "name": "Brian S. Alper"
    }
  ],
  "relatedArtifact": [
    {
      "type": "derived-from",
      "resourceReference": {
        "reference": "Citation/179613",
        "type": "Citation",
        "display": "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Different comparison (ADT versus ADT plus estramustine)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179628",
        "type": "Citation",
        "display": "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Different comparison (ADT versus ADT plus chemotherapy without docetaxel)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179631",
        "type": "Citation",
        "display": "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Different comparison (ADT versus ADT plus radiotherapy)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179627",
        "type": "Citation",
        "display": "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Different comparison (ADT versus ADT plus radiotherapy)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179626",
        "type": "Citation",
        "display": "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Different comparison (ADT versus ADT plus radiotherapy)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179625",
        "type": "Citation",
        "display": "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Nonrandomized"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179629",
        "type": "Citation",
        "display": "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Neoadjuvant treatment"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179624",
        "type": "Citation",
        "display": "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Nonrandomized"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179622",
        "type": "Citation",
        "display": "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "High-risk localized prostate cancer"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179621",
        "type": "Citation",
        "display": "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Locally advanced or metastatic (without metastatic subgroup analysis)"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179630",
        "type": "Citation",
        "display": "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."
      }
    },
    {
      "type": "contains",
      "classifier": [
        {
          "text": "Nonrandomized"
        }
      ],
      "resourceReference": {
        "reference": "Citation/179623",
        "type": "Citation",
        "display": "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."
      }
    }
  ]
}